The emerging role of insulin and insulin-like growth factor signaling in cancer stem cells

Frontiers in Endocrinology

Volumn 5, Issue FEB, 2014, Pages

  Malaguarnera, Roberta ^a   Belfiore, Antonino ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Cancer stem cells; EMT; IGF I; IGF II; IGF IR; Insulin; Insulin receptor; Stem cells

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FIBRONECTIN; FIGITUMUMAB; GEFITINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INSULIN RECEPTOR; KRUPPEL LIKE FACTOR 6; MYC PROTEIN; NERVE CELL ADHESION MOLECULE; OCCLUDIN; OCTAMER TRANSCRIPTION FACTOR 4; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN B RECEPTOR; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR SOX2; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR ZEB1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG; UVOMORULIN; VIMENTIN;

CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENICITY; CELL CONTACT; CELL DIFFERENTIATION; CELL GROWTH; CELL RENEWAL; CELL SURVIVAL; CLINICAL TRIAL (TOPIC); EMBRYO DEVELOPMENT; EPITHELIAL MESENCHYMAL TRANSITION; GENE MUTATION; GLYCOGEN SYNTHESIS; HUMAN; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION;

EID: 84901002030     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2014.00010     Document Type: Review

References (159)

1. Brogiolo W, Stocker H, Ikeya T, Rintelen F, Fernandez R, Hafen E. An evolutionarily conserved function of the Drosophila insulin receptor and insulin-like peptides in growth control. Curr Biol (2001) 11:213-21. doi: 10.1016/S0960-9822(01)00068-9.
2. Valentinis B, Baserga R. IGF-I receptor signalling in transformation and differentiation. Mol Pathol (2001) 54:133-7. doi:10.1136/mp.54.3.133.
3. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev (2009) 30:586-623. doi:10.1210/er.2008-0047.
4. Malaguarnera R, Sacco A, Voci C, Pandini G, Vigneri R, Belfiore A. Proinsulin binds with high affinity the insulin receptor isoform A and predominantly activates the mitogenic pathway. Endocrinology (2012) 153(5):2152-63. doi:10.1210/en.2011-1843.
5. El-Shewy HM, Luttrell LM. Insulin-like growth factor-2/mannose-6 phosphate receptors. Vitam Horm (2009) 80:667-97. doi:10.1016/S0083-6729(08)00624-9.
6. Gallagher EJ, LeRoith D. Mini review: IGF, insulin, and cancer. Endocrinology (2011) 152:2546-51. doi:10.1210/en.2011-0231.
7. Baserga R, Peruzzi F, Reiss K. The IGF-1 receptor in cancer biology. Int J Cancer (2003) 107:873-7. doi:10.1002/ijc.11487.
8. LeRoith D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Lett (2003) 195:127-37. doi:10.1016/S0304-3835(03)00159-9.
9. Pollak M. Targeting insulin and insulin-like growth factor signalling in oncology. Curr Opin Pharmacol (2008) 8:384-92. doi:10.1016/j.coph.2008.07.004.
10. Baserga R. The decline and fall of the IGF-I receptor. J Cell Physiol (2013) 228:675-9. doi:10.1002/jcp.24217.
11. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature (2001) 414:105-11. doi:10.1038/35102167.
12. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell (2006) 127:469-80. doi:10.1016/j.cell.2006.10.018.
13. Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea-a paradigm shift. Cancer Res (2006) 66:1883-6. doi:10.1158/0008-5472.CAN-05-3153.
14. Mani SA, Guo W, Liao M-J, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell (2008) 133:704-15. doi:10.1016/j.cell.2008.03.027.
15. Bendall SC, Stewart MH, Menendez P, George D, Vijayaragavan K, Werbowetski-Ogilvie T, et al. IGF and FGF cooperatively establish the regulatory stem cell niche of pluripotent human cells in vitro. Nature (2007) 448:1015-21. doi:10.1038/nature06027.
16. McDevitt TC, Laflamme MA, Murry CE. Proliferation of cardiomyocytes derived from human embryonic stem cells is mediated via the IGF/PI 3-kinase/Akt signaling pathway. J Mol Cell Cardiol (2005) 39:865-73. doi:10.1016/j.yjmcc.2005.09.007.
17. Stachelscheid H, Ibrahim H, Koch L, Schmitz A, Tscharntke M, Wunderlich FT, et al. Epidermal insulin/IGF-1 signalling control interfollicular morphogenesis and proliferative potential through Rac activation. EMBO J (2008) 27:2091-101. doi:10.1038/emboj.2008.141.
18. Yan YP, Sailor KA, Vemuganti R, Dempsey RJ. Insulin-like growth factor-1 is an endogenous mediator of focal ischemia-induced neural progenitor proliferation. Eur J Neurosci (2006) 24:45-54. doi:10.1111/j.1460-9568.2006.04872.x.
19. Savarese TM, Strohsnitter WC, Low HP, Liu Q, Baik I, Okulicz W, et al. Correlation of umbilical cord blood hormones and growth factors with stem cell potential: implications for the prenatal origin of breast cancer hypothesis. Breast Cancer Res (2007) 9:R29. doi:10.1186/bcr1674.
20. Ivanova NB, Dimos JT, Schaniel C, Hackney JA, Moore KA, Lemischka IR. A stem cell molecular signature. Science (2002) 298:601-4. doi:10.1126/science.1073823.
21. Ziegler AN, Schneider JS, Qin M, Tyler WA, Pintar JE, Fraidenraich D, et al. IGF-II promotes stemness of neural restricted precursors. Stem Cells (2012) 30:1265-76. doi:10.1002/stem.1095.
22. Ziegler AN, Chidambaram S, Forbes BE, Wood TL, Levison SW. IGF-II and IGF-II analogs with enhanced insulin receptor-A binding affinity promote neural stem cell expansion. J Biol Chem (2014). Available from: http://www.ncbi.nlm.nih.gov/pubmed/24398690 doi:10.1074/jbc. M113.537597.
23. Malaguarnera R, Frasca F, Garozzo A, Giani F, Pandini G, Vella V, et al. Insulin receptor isoforms and insulin-like growth factor receptor in human follicular cell precursors from papillary thyroid cancer and normal thyroid. J Clin Endocrinol Metab (2011) 96:766-74. doi:10.1210/jc.2010-1255.
24. Shan J, Shen J, Liu L, Xia F, Xu C, Duan G, et al. Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma. Hepatology (2012) 56:1004-14. doi:10.1002/hep.25745.
25. Chang W-W, Lin R-J, Yu J, Chang W-Y, Fu C-H, Lai AC-Y, et al. The expression and significance of insulin-like growth factor-1 receptor and its pathway on breast cancer stem/progenitors. Breast Cancer Res (2013) 15:R39. doi:10.1186/bcr3423.
26. Xu C, Xie D, Yu S-C, Yang X-J, He L-R, Yang J, et al. β-Catenin/POU5F1/SOX2 transcription factor complex mediates IGF-I receptor signaling and predicts poor prognosis in lung adenocarcinoma. Cancer Res (2013) 73:3181-9. doi:10.1158/0008-5472.CAN-12-4403.
27. Dallas NA, Xia L, Fan F, Gray MJ, Gaur P, van Buren G II, et al. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res (2009) 69:1951-7. doi:10.1158/0008-5472.CAN-08-2023.
28. Hart LS, DolloffNG, Dicker DT, Koumenis C, Christensen JG, Grimberg A, et al. Human colon cancer stem cells are enriched by insulin-like growth factor-1 and are sensitive to figitumumab. Cell Cycle (2011) 10:2331-8. doi:10.4161/cc.10.14.16418.
29. Bodzin AS, Wei Z, Hurtt R, Gu T, Doria C. Gefitinib resistance in HCC Mahlavu cells: upregulation of CD133 expression, activation of IGF-1R signaling pathway, and enhancement of IGF-1R nuclear translocation. J Cell Physiol (2012) 227:2947-52. doi:10.1002/jcp.23041.
30. Aleksic T, Chitnis MM, Perestenko OV, Gao S, Thomas PH, Turner GD, et al. Type 1 insulin-like growth factor receptor translocates to the nucleus of human tumor cells. Cancer Res (2010) 70:6412-9. doi:10.1158/0008-5472.CAN-10-0052.
31. Sarfstein R, Pasmanik-Chor M, Yeheskel A, Edry L, Shomron N, Warman N, et al. Insulin-like growth factor-I receptor (IGF-IR) translocates to nucleus and autoregulates IGF-IR gene expression in breast cancer cells. J Biol Chem (2012) 287:2766-76. doi:10.1074/jbc. M111.281782.
32. Medyouf H, Gusscott S, Wang H, Tseng J-C, Wai C, Nemirovsky O, et al. High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by notch signaling. J Exp Med (2011) 208:1809-22. doi:10.1084/jem.20110121.
33. Jenkins CR, Shevchuk OO, Giambra V, Lam SH, Carboni JM, Gottardis MM, et al. IGF signaling contributes to malignant transformation of hematopoietic progenitors by the MLL-AF9 oncoprotein. Exp Hematol (2012) 40:715.e-23.e. doi:10.1016/j.exphem.2012.05.003.
34. Fang X, Cai Y, Liu J, Wang Z, Wu Q, Zhang Z, et al. Twist2 contributes to breast cancer progression by promoting an epithelial-mesenchymal transition and cancer stem-like cell self-renewal. Oncogene (2011) 30:4707-20. doi:10.1038/onc.2011.181.
35. Kurrey NK, Jalgaonkar SP, Joglekar AV, Ghanate AD, Chaskar PD, Doiphode RY, et al. Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells (2009) 27:2059-68. doi:10.1002/stem.154.
36. Hwang W-L, Yang M-H, Tsai M-L, Lan H-Y, Su S-H, Chang S-C, et al. SNAIL regulates interleukin-8 expression, stem cell-like activity, and tumorigenicity of human colorectal carcinoma cells. Gastroenterology (2011) 141:.e1-5. doi:10.1053/j.gastro.2011.04.008.
37. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer (2007) 7:415-28. doi:10.1038/nrc2131.
38. Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol (2009) 11:1487-95. doi:10.1038/ncb1998.
39. Dupont J, Fernandez AM, Glackin CA, Helman L, LeRoith D. Insulin-like growth factor 1 (IGF-1)-induced twist expression is involved in the anti-apoptotic effects of the IGF-1 receptor. J Biol Chem (2001) 276:26699-707. doi:10.1074/jbc. M102664200.
40. Graham TR, Zhau HE, Odero-Marah VA, Osunkoya AO, Kimbro KS, Tighiouart M, et al. Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res (2008) 68:2479-88. doi:10.1158/0008-5472.CAN-07-2559.
41. Yost C, Torres M, Miller JR, Huang E, Kimelman D, Moon RT. The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev (1996) 10:1443-54. doi:10.1101/gad.10.12.1443.
42. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev (1998) 12:3499-511. doi:10.1101/gad.12.22.3499.
43. Gupta PB, Kuperwasser C, Brunet J-P, Ramaswamy S, Kuo W-L, Gray JW, et al. The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nat Genet (2005) 37:1047-54. doi:10.1038/ng1634.
44. Zhou BP, Deng J, Xia W, Xu J, Li YM, Gunduz M, et al. Dual regulation of snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol (2004) 6:931-40. doi:10.1038/ncb1173.
45. Bachelder RE, Yoon S-O, Franci C, de Herreros AG, Mercurio AM. Glycogen synthase kinase-3 is an endogenous inhibitor of snail transcription: implications for the epithelial-mesenchymal transition. J Cell Biol (2005) 168:29-33. doi:10.1083/jcb.200409067.
46. Kao S-H, Wang W-L, Chen C-Y, Chang Y-L, Wu Y-Y, Wang Y-T, et al. GSK3β controls epithelial-mesenchymal transition and tumor metastasis by CHIP-mediated degradation of Slug. Oncogene (2013). Available from: http://www.ncbi.nlm.nih.gov/pubmed/23851495 doi:10.1038/onc.2013.279.
47. John JK, Paraiso KHT, Rebecca VW, Cantini LP, Abel EV, Pagano N, et al. GSK3β inhibition blocks melanoma cell/host interactions by downregulating N-cadherin expression and decreasing FAK phosphorylation. J Invest Dermatol (2012) 132:2818-27. doi:10.1038/jid.2012.237.
48. PapkoffJ, Aikawa M. WNT-1 and HGF regulate GSK3 beta activity and beta-catenin signaling in mammary epithelial cells. Biochem Biophys Res Commun (1998) 247:851-8. doi:10.1006/bbrc.1998.8888.
49. Davies MA, Stemke-Hale K, Tellez C, Calderone TL, Deng W, Prieto VG, et al. A novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer (2008) 99:1265-8. doi:10.1038/sj.bjc.6604637.
50. Paraiso KHT, Xiang Y, Rebecca VW, Abel EV, Chen YA, Munko AC, et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res (2011) 71:2750-60. doi:10.1158/0008-5472.CAN-10-2954.
51. Guvakova MA, Surmacz E. The activated insulin-like growth factor I receptor induces depolarization in breast epithelial cells characterized by actin filament disassembly and tyrosine dephosphorylation of FAK, Cas, and paxillin. Exp Cell Res (1999) 251:244-55. doi:10.1006/excr.1999.4566.
52. Julien S, Puig I, Caretti E, Bonaventure J, Nelles L, van Roy F, et al. Activation of NF-kappaB by Akt upregulates snail expression and induces epithelium mesenchyme transition. Oncogene (2007) 26:7445-56. doi:10.1038/sj.onc.1210546.
53. Chua HL, Bhat-Nakshatri P, Clare SE, Morimiya A, Badve S, Nakshatri H. NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2. Oncogene (2007) 26:711-24. doi:10.1038/sj.onc.1209808.
54. Barberà MJ, Puig I, Domínguez D, Julien-Grille S, Guaita-Esteruelas S, Peiró S, et al. Regulation of snail transcription during epithelial to mesenchymal transition of tumor cells. Oncogene (2004) 23:7345-54. doi:10.1038/sj.onc.1207990.
55. Wu Y, Deng J, Rychahou PG, Qiu S, Evers BM, Zhou BP. Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion. Cancer Cell (2009) 15:416-28. doi:10.1016/j.ccr.2009.03.016.
56. Irie HY, Pearline RV, Grueneberg D, Hsia M, Ravichandran P, Kothari N, et al. Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. J Cell Biol (2005) 171:1023-34. doi:10.1083/jcb.200505087.
57. Dearth RK, Cui X, Kim H-J, Kuiatse I, Lawrence NA, Zhang X, et al. Mammary tumorigenesis and metastasis caused by overexpression of insulin receptor substrate 1 (IRS-1) or IRS-2. Mol Cell Biol (2006) 26:9302-14. doi:10.1128/MCB.00260-06.
58. Sorokin AV, Chen J. MEMO1, a new IRS1-interacting protein, induces epithelial-mesenchymal transition in mammary epithelial cells. Oncogene (2013) 32:3130-8. doi:10.1038/onc.2012.327.
59. Sivakumar R, Koga H, Selvendiran K, Maeyama M, Ueno T, Sata M. Autocrine loop for IGF-I receptor signaling in SLUG-mediated epithelial-mesenchymal transition. Int J Oncol (2009) 34:329-38. doi:10.3892/ijo_00000155.
60. Frolov MV, Dyson NJ. Molecular mechanisms of E2F-dependent activation and pRB-mediated repression. J Cell Sci (2004) 117:2173-81. doi:10.1242/jcs.01227.
61. Sacco A, Morcavallo A, Pandini G, Vigneri R, Belfiore A. Differential signaling activation by insulin and insulin-like growth factors I and II upon binding to insulin receptor isoform A. Endocrinology (2009) 150:3594-602. doi:10.1210/en.2009-0377.
62. Zhao H, Desai V, Wang J, Epstein DM, Miglarese M, Buck E. Epithelial-mesenchymal transition predicts sensitivity to the dual IGF-1R/IR inhibitor OSI-906 in hepatocellular carcinoma cell lines. Mol Cancer Ther (2012) 11:503-13. doi:10.1158/1535-7163.MCT-11-0327.
63. Vella V, Pandini G, Sciacca L, Mineo R, Vigneri R, Pezzino V, et al. A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer. J Clin Endocrinol Metab (2002) 87:245-54. doi:10.1210/jc.87.1.245.
64. Yang Y, Yee D. Targeting insulin and insulin-like growth factor signaling in breast cancer. J Mammary Gland Biol Neoplasia (2012) 17:251-61. doi:10.1007/s10911-012-9268-y.
65. Garofalo C, Manara MC, Nicoletti G, Marino MT, Lollini PL, AstolfiA, et al. Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling. Oncogene (2011) 30(24):2730-40. doi:10.1038/onc.2010.640.
66. Pandini G, Frasca F, Mineo R, Sciacca L, Vigneri R, Belfiore A. Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem (2002) 277:39684-95. doi:10.1074/jbc. M202766200.
67. Andres SF, Simmons JG, Mah AT, Santoro MA, Van Landeghem L, Lund PK. Insulin receptor isoform switching in intestinal stem cells, progenitors, differentiated lineages and tumors: evidence that IR-B limits proliferation. J Cell Sci (2013) 126:5645-56. doi:10.1242/jcs.132985.
68. Sciacca L, Prisco M, Wu A, Belfiore A, Vigneri R, Baserga R. Signaling differences from the A and B isoforms of the insulin receptor (IR) in 32D cells in the presence or absence of IR substrate-1. Endocrinology (2003) 144:2650-8. doi:10.1210/en.2002-0136.
69. Liu J, Visser-Grieve S, Boudreau J, Yeung B, Lo S, Chamberlain G, et al. Insulin activates the insulin receptor to downregulate the PTEN tumour suppressor. Oncogene (2013). Available from: http://www.ncbi.nlm.nih.gov/pubmed/23995781 doi:10.1038/onc.2013.347.
70. Kosaki A, Webster NJ. Effect of dexamethasone on the alternative splicing of the insulin receptor mRNA and insulin action in HepG2 hepatoma cells. J Biol Chem (1993) 268:21990-6.
71. Warzecha CC, Carstens RP. Complex changes in alternative pre-mRNA splicing play a central role in the epithelial-to-mesenchymal transition (EMT). Semin Cancer Biol (2012) 22:417-27. doi:10.1016/j.semcancer.2012.04.003.
72. Talukdar I, Sen S, Urbano R, Thompson J, Yates JR, Webster NJG. hnRNP A1 and hnRNP F modulate the alternative splicing of exon 11 of the insulin receptor gene. PLoS One (2011) 6:e27869. doi:10.1371/journal.pone.0027869.
73. Chettouh H, Fartoux L, Aoudjehane L, Wendum D, Clapéron A, Chrétien Y, et al. Mitogenic insulin receptor-A is overexpressed in human hepatocellular carcinoma due to EGFR-mediated dysregulation of RNA splicing factors. Cancer Res (2013) 73:3974-86. doi:10.1158/0008-5472.CAN-12-3824.
74. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell (2007) 131:861-72. doi:10.1016/j.cell.2007.11.019.
75. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science (2007) 318:1917-20. doi:10.1126/science.1151526.
76. Hong H, Takahashi K, Ichisaka T, Aoi T, Kanagawa O, Nakagawa M, et al. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature (2009) 460:1132-5. doi:10.1038/nature08235.
77. Zbinden M, Duquet A, Lorente-Trigos A, Ngwabyt S-N, Borges I, Ruiz i Altaba A. NANOG regulates glioma stem cells and is essential in vivo acting in a cross-functional network with GLI1 and p53. EMBO J (2010) 29:2659-74. doi:10.1038/emboj.2010.137.
78. Pan G, Thomson JA. Nanog and transcriptional networks in embryonic stem cell pluripotency. Cell Res (2007) 17:42-9. doi:10.1038/sj.cr.7310125.
79. Golubovskaya VM. FAK and Nanog cross talk with p53 in cancer stem cells. Anticancer Agents Med Chem (2013) 13:576-80. doi:10.2174/1871520611313040006.
80. Schubert J, Brabletz T. p53 Spreads out further: suppression of EMT and stemness by activating miR-200c expression. Cell Res (2011) 21:705-7. doi:10.1038/cr.2011.62.
81. Kogan-Sakin I, Tabach Y, Buganim Y, Molchadsky A, Solomon H, Madar S, et al. Mutant p53(R175H) upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells. Cell Death Differ (2011) 18:271-81. doi:10.1038/cdd.2010.94.
82. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature (2005) 434:843-50. doi:10.1038/nature03319.
83. Fre S, Vignjevic D, Schoumacher M, Duffy SL, Janssen K-P, Robine S, et al. Epithelial morphogenesis and intestinal cancer: new insights in signaling mechanisms. Adv Cancer Res (2008) 100:85-111. doi:10.1016/S0065-230X(08)00003-1.
84. Takahashi K, Suzuki K. Association of insulin-like growth-factor-I-induced DNA synthesis with phosphorylation and nuclear exclusion of p53 in human breast cancer MCF-7 cells. Int J Cancer (1993) 55:453-8. doi:10.1002/ijc.2910550322.
85. Mimeault M, Batra SK. Altered gene products involved in the malignant reprogramming of cancer stem/progenitor cells and multitargeted therapies. Mol Aspects Med (2013). Available from: http://www.ncbi.nlm.nih.gov/pubmed/23994756 doi:10.1016/j.mam.2013.08.001.
86. Catrina SB, Botusan IR, Rantanen A, Catrina AI, Pyakurel P, Savu O, et al. Hypoxia-inducible factor-1alpha and hypoxia-inducible factor-2alpha are expressed in Kaposi sarcoma and modulated by insulin-like growth factor-I. Clin Cancer Res (2006) 12:4506-14. doi:10.1158/1078-0432.CCR-05-2473.
87. Semenza GL. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest (2013) 123:3664-71. doi:10.1172/JCI67230.
88. Werner H, Maor S. The insulin-like growth factor-I receptor gene: a downstream target for oncogene and tumor suppressor action. Trends Endocrinol Metab (2006) 17:236-42. doi:10.1016/j.tem.2006.06.007.
89. Girnita L, Girnita A, Larsson O. Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor. Proc Natl Acad Sci U S A (2003) 100:8247-52. doi:10.1073/pnas.1431613100.
90. Webster NJ, Resnik JL, Reichart DB, Strauss B, Haas M, Seely BL. Repression of the insulin receptor promoter by the tumor suppressor gene product p53: a possible mechanism for receptor overexpression in breast cancer. Cancer Res (1996) 56:2781-8.
91. Shah SN, Resar LMS. High mobility group A1 and cancer: potential biomarker and therapeutic target. Histol Histopathol (2012) 27:567-79.
92. Pegoraro S, Ros G, Piazza S, Sommaggio R, Ciani Y, Rosato A, et al. HMGA1 promotes metastatic processes in basal-like breast cancer regulating EMT and stemness. Oncotarget (2013) 4:1293-308.
93. Belton A, Gabrovsky A, Bae YK, Reeves R, Iacobuzio-Donahue C, Huso DL, et al. HMGA1 induces intestinal polyposis in transgenic mice and drives tumor progression and stem cell properties in colon cancer cells. PLoS One (2012) 7:e30034. doi:10.1371/journal.pone.0030034.
94. Frasca F, Rustighi A, Malaguarnera R, Altamura S, Vigneri P, Del Sal G, et al. HMGA1 inhibits the function of p53 family members in thyroid cancer cells. Cancer Res (2006) 66:2980-9. doi:10.1158/0008-5472.CAN-05-2637.
95. Foti D, Iuliano R, Chiefari E, Brunetti A. A nucleoprotein complex containing Sp1, C/EBP beta, and HMGI-Y controls human insulin receptor gene transcription. Mol Cell Biol (2003) 23:2720-32. doi:10.1128/MCB.23.8.2720-2732.2003.
96. Aiello A, Pandini G, Sarfstein R, Werner H, Manfioletti G, Vigneri R, et al. HMGA1 protein is a positive regulator of the insulin-like growth factor-I receptor gene. Eur J Cancer (2010) 46:1919-26. doi:10.1016/j.ejca.2010.02.050.
97. Sarfstein R, Belfiore A, Werner H. Identification of insulin-like growth factor-I receptor (IGF-IR) gene promoter-binding proteins in estrogen receptor (ER)-positive and ER-depleted breast cancer cells. Cancers (Basel) (2010) 2:233-61. doi:10.3390/cancers2020233.
98. Hudelist G, Wagner T, Rosner M, Fink-Retter A, Gschwantler-Kaulich D, Czerwenka K, et al. Intratumoral IGF-I protein expression is selectively upregulated in breast cancer patients with BRCA1/2 mutations. Endocr Relat Cancer (2007) 14:1053-62. doi:10.1677/ERC-06-0075.
99. Zechner D, Fujita Y, Hülsken J, Müller T, Walther I, Taketo MM, et al. beta-Catenin signals regulate cell growth and the balance between progenitor cell expansion and differentiation in the nervous system. Dev Biol (2003) 258:406-18. doi:10.1016/S0012-1606(03)00123-4.
100. Reya T. Wnt signalling in stem cells and cancer. Nature (2005) 434:843-50. doi:10.1038/nature03319.
101. Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet (2004) 5:691-701. doi:10.1038/nrg1427.
102. Sato N, Meijer L, Skaltsounis L, Greengard P, Brivanlou AH. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat Med (2004) 10:55-63. doi:10.1038/nm979.
103. Wang Y, Krivtsov AV, Sinha AU, North TE, Goessling W, Feng Z, et al. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science (2010) 327:1650-3. doi:10.1126/science.1186624.
104. Scheller M, Huelsken J, Rosenbauer F, Taketo MM, Birchmeier W, Tenen DG, et al. Hematopoietic stem cell and multilineage defects generated by constitutive beta-catenin activation. Nat Immunol (2006) 7:1037-47. doi:10.1038/ni1387.
105. Yeung J, Esposito MT, Gandillet A, Zeisig BB, Griessinger E, Bonnet D, et al. β-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell (2010) 18:606-18. doi:10.1016/j.ccr.2010.10.032.
106. Polakis P. Wnt signaling and cancer. Genes Dev (2000) 14:1837-51. doi:10.1101/gad.14.15.1837.
107. Barker N, Ridgway RA, van Es JH, van de Wetering M, Begthel H, van den Born M, et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature (2009) 457:608-11. doi:10.1038/nature07602.
108. de Sousa EMF, Vermeulen L, Richel D, Medema JP. Targeting Wnt signaling in colon cancer stem cells. Clin Cancer Res (2011) 17:647-53. doi:10.1158/1078-0432.CCR-10-1204.
109. Vermeulen L, De Sousa E, Melo F, van der Heijden M, Cameron K, de Jong JH, et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol (2010) 12:468-76. doi:10.1038/ncb2048.
110. Harrison H, Farnie G, Brennan KR, Clarke RB. Breast cancer stem cells: something out of notching? Cancer Res (2010) 70:8973-6. doi:10.1158/0008-5472.CAN-10-1559.
111. Grigoryan T, Wend P, Klaus A, Birchmeier W. Deciphering the function of canonical Wnt signals in development and disease: conditional loss-and gain-of-function mutations of beta-catenin in mice. Genes Dev (2008) 22:2308-41. doi:10.1101/gad.1686208.
112. Wang H, Zhang G, Zhang H, Zhang F, Zhou B, Ning F, et al. Acquisition of epithelial-mesenchymal transition phenotype and cancer stem cell-like properties in cisplatin-resistant lung cancer cells through AKT/β-catenin/snail signaling pathway. Eur J Pharmacol (2013) 723C:156-66. doi:10.1016/j.ejphar.2013.12.004.
113. Playford MP, Bicknell D, Bodmer WF, Macaulay VM. Insulin-like growth factor 1 regulates the location, stability, and transcriptional activity of beta-catenin. Proc Natl Acad Sci U S A (2000) 97:12103-8. doi:10.1073/pnas.210394297.
114. Vanamala J, Reddivari L, Radhakrishnan S, Tarver C. Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways. BMC Cancer (2010) 10:238. doi:10.1186/1471-2407-10-238.
115. Davies M, Gupta S, Goldspink G, Winslet M. The insulin-like growth factor system and colorectal cancer: clinical and experimental evidence. Int J Colorectal Dis (2006) 21:201-8. doi:10.1007/s00384-005-0776-8.
116. Polakis P. The many ways of Wnt in cancer. Curr Opin Genet Dev (2007) 17:45-51. doi:10.1016/j.gde.2006.12.007.
117. Desbois-Mouthon C, Cadoret A, Blivet-Van Eggelpoël MJ, Bertrand F, Cherqui G, Perret C, et al. Insulin and IGF-1 stimulate the beta-catenin pathway through two signalling cascades involving GSK-3beta inhibition and Ras activation. Oncogene (2001) 20:252-9. doi:10.1038/sj.onc.1204064.
118. Ye P, Hu Q, Liu H, Yan Y, D'Ercole AJ. beta-catenin mediates insulin-like growth factor-I actions to promote cyclin D1 mRNA expression, cell proliferation and survival in oligodendroglial cultures. Glia (2010) 58:1031-41. doi:10.1002/glia.20984.
119. Gehmert S, Sadat S, Song Y-H, Yan Y, Alt E. The anti-apoptotic effect of IGF-1 on tissue resident stem cells is mediated via PI3-kinase dependent secreted frizzled related protein 2 (Sfrp2) release. Biochem Biophys Res Commun (2008) 371:752-5. doi:10.1016/j.bbrc.2008.04.151.
120. Morali OG, Delmas V, Moore R, Jeanney C, Thiery JP, Larue L. IGF-II induces rapid beta-catenin relocation to the nucleus during epithelium to mesenchyme transition. Oncogene (2001) 20:4942-50. doi:10.1038/sj.onc.1204660.
121. Chen J, Wu A, Sun H, Drakas R, Garofalo C, Cascio S, et al. Functional significance of type 1 insulin-like growth factor-mediated nuclear translocation of the insulin receptor substrate-1 and beta-catenin. J Biol Chem (2005) 280:29912-20. doi:10.1074/jbc. M504516200.
122. Bommer GT, Feng Y, Iura A, Giordano TJ, Kuick R, Kadikoy H, et al. IRS1 regulation by Wnt/beta-catenin signaling and varied contribution of IRS1 to the neoplastic phenotype. J Biol Chem (2010) 285:1928-38. doi:10.1074/jbc. M109.060319.
123. Rubin R, Arzumanyan A, Soliera AR, Ross B, Peruzzi F, Prisco M. Insulin receptor substrate (IRS)-1 regulates murine embryonic stem (mES) cells self-renewal. J Cell Physiol (2007) 213:445-53. doi:10.1002/jcp.21185.
124. Espinoza I, Miele L. Deadly crosstalk: notch signaling at the intersection of EMT and cancer stem cells. Cancer Lett (2013) 341:41-5. doi:10.1016/j.canlet.2013.08.027.
125. Leong KG, Karsan A. Recent insights into the role of notch signaling in tumorigenesis. Blood (2006) 107:2223-33. doi:10.1182/blood-2005-08-3329.
126. Wang Z, Li Y, Kong D, Sarkar FH. The role of notch signaling pathway in epithelial-mesenchymal transition (EMT) during development and tumor aggressiveness. Curr Drug Targets (2010) 11:745-51. doi:10.2174/138945010791170860.
127. Sethi S, Macoska J, Chen W, Sarkar FH. Molecular signature of epithelial-mesenchymal transition (EMT) in human prostate cancer bone metastasis. Am J Transl Res (2010) 3:90-9.
128. Leong KG, Niessen K, Kulic I, Raouf A, Eaves C, Pollet I, et al. Jagged1-mediated notch activation induces epithelial-to-mesenchymal transition through slug-induced repression of E-cadherin. J Exp Med (2007) 204:2935-48. doi:10.1084/jem.20071082.
129. Brabletz S, Bajdak K, Meidhof S, Burk U, Niedermann G, Firat E, et al. The ZEB1/miR-200 feedback loop controls notch signalling in cancer cells. EMBO J (2011) 30:770-82. doi:10.1038/emboj.2010.349.
130. Yang Y, Ahn Y-H, Gibbons DL, Zang Y, Lin W, Thilaganathan N, et al. The notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200-dependent pathway in mice. J Clin Invest (2011) 121:1373-85. doi:10.1172/JCI42579.
131. Hassan KA, Wang L, Korkaya H, Chen G, Maillard I, Beer DG, et al. Notch pathway activity identifies cells with cancer stem cell-like properties and correlates with worse survival in lung adenocarcinoma. Clin Cancer Res (2013) 19:1972-80. doi:10.1158/1078-0432.CCR-12-0370.
132. Apostolou P, Toloudi M, Ioannou E, Kourtidou E, Chatziioannou M, Kopic A, et al. Study of the interaction among notch pathway receptors, correlation with stemness, as well as their interaction with CD44, dipeptidyl peptidase-IV, hepatocyte growth factor receptor and the SETMAR transferase, in colon cancer stem cells. J Recept Signal Transduct Res (2013) 33:353-8. doi:10.3109/10799893.2013.828072.
133. Zhang X-P, Zheng G, Zou L, Liu H-L, Hou L-H, Zhou P, et al. Notch activation promotes cell proliferation and the formation of neural stem cell-like colonies in human glioma cells. Mol Cell Biochem (2008) 307:101-8. doi:10.1007/s11010-007-9589-0.
134. Mazzone M, Selfors LM, Albeck J, Overholtzer M, Sale S, Carroll DL, et al. Dose-dependent induction of distinct phenotypic responses to notch pathway activation in mammary epithelial cells. Proc Natl Acad Sci U S A (2010) 107:5012-7. doi:10.1073/pnas.1000896107.
135. Eliasz S, Liang S, Chen Y, De Marco MA, Machek O, Skucha S, et al. Notch-1 stimulates survival of lung adenocarcinoma cells during hypoxia by activating the IGF-1R pathway. Oncogene (2010) 29:2488-98. doi:10.1038/onc.2010.7.
136. Hsu H-J, Drummond-Barbosa D. Insulin signals control the competence of the Drosophila female germline stem cell niche to respond to notch ligands. Dev Biol (2011) 350:290-300. doi:10.1016/j.ydbio.2010.11.032.
137. Ouellet J, Li S, Roy R. Notch signalling is required for both dauer maintenance and recovery in C. elegans. Development (2008) 135:2583-92. doi:10.1242/dev.012435.
138. McMahon AP, Ingham PW, Tabin CJ. Developmental roles and clinical significance of hedgehog signaling. Curr Top Dev Biol (2003) 53:1-114.
139. Milla LA, González-Ramírez CN, Palma V. Sonic hedgehog in cancer stem cells: a novel link with autophagy. Biol Res (2012) 45:223-30. doi:10.4067/S0716-97602012000300004.
140. Sanchez P, Hernández AM, Stecca B, Kahler AJ, DeGueme AM, Barrett A, et al. Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOG-GLI1 signaling. Proc Natl Acad Sci U S A (2004) 101:12561-6. doi:10.1073/pnas.0404956101.
141. Athar M, Tang X, Lee JL, Kopelovich L, Kim AL. Hedgehog signalling in skin development and cancer. Exp Dermatol (2006) 15:667-77. doi:10.1111/j.1600-0625.2006.00473.x.
142. Yang Z-J, Ellis T, Markant SL, Read T-A, Kessler JD, Bourboulas M, et al. Medulloblastoma can be initiated by deletion of patched in lineage-restricted progenitors or stem cells. Cancer Cell (2008) 14:135-45. doi:10.1016/j.ccr.2008.07.003.
143. Katoh Y, Katoh M. Hedgehog signaling pathway and gastrointestinal stem cell signaling network (review). Int J Mol Med (2006) 18:1019-23.
144. Maitah MY, Ali S, Ahmad A, Gadgeel S, Sarkar FH. Up-regulation of sonic hedgehog contributes to TGF-β1-induced epithelial to mesenchymal transition in NSCLC cells. PLoS One (2011) 6:e16068. doi:10.1371/journal.pone.0016068.
145. Dahmane N, Sánchez P, Gitton Y, Palma V, Sun T, Beyna M, et al. The sonic hedgehog-Gli pathway regulates dorsal brain growth and tumorigenesis. Development (2001) 128:5201-12.
146. Ruiz i Altaba A, Stecca B, Sánchez P. Hedgehog-Gli signaling in brain tumors: stem cells and paradevelopmental programs in cancer. Cancer Lett (2004) 204:145-57. doi:10.1016/S0304-3835(03)00451-8.
147. Ahlfeld J, Favaro R, Pagella P, Kretzschmar HA, Nicolis S, Schüller U. Sox2 requirement in sonic hedgehog-associated medulloblastoma. Cancer Res (2013) 73:3796-807. doi:10.1158/0008-5472.CAN-13-0238.
148. Takanaga H, Tsuchida-Straeten N, Nishide K, Watanabe A, Aburatani H, Kondo T. Gli2 is a novel regulator of sox2 expression in telencephalic neuroepithelial cells. Stem Cells (2009) 27:165-74. doi:10.1634/stemcells.2008-0580.
149. Clement V, Sanchez P, de Tribolet N, Radovanovic I, Ruiz i Altaba A. HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol (2007) 17:165-72. doi:10.1016/j.cub.2006.11.033.
150. Rao G, Pedone CA, Del Valle L, Reiss K, Holland EC, Fults DW. Sonic hedgehog and insulin-like growth factor signaling synergize to induce medulloblastoma formation from nestin-expressing neural progenitors in mice. Oncogene (2004) 23:6156-62. doi:10.1038/sj.onc.1207818.
151. Hahn H, Wojnowski L, Specht K, Kappler R, Calzada-Wack J, Potter D, et al. Patched target Igf2 is indispensable for the formation of medulloblastoma and rhabdomyosarcoma. J Biol Chem (2000) 275:28341-4. doi:10.1074/jbc. C000352200.
152. Fernandez C, Tatard VM, Bertrand N, Dahmane N. Differential modulation of Sonic-hedgehog-induced cerebellar granule cell precursor proliferation by the IGF signaling network. Dev Neurosci (2010) 32:59-70. doi:10.1159/000274458.
153. Corcoran RB, Bachar Raveh T, Barakat MT, Lee EY, Scott MP. Insulin-like growth factor 2 is required for progression to advanced medulloblastoma in patched1 heterozygous mice. Cancer Res (2008) 68:8788-95. doi:10.1158/0008-5472.CAN-08-2135.
154. Hsieh A, Ellsworth R, Hsieh D. Hedgehog/GLI1 regulates IGF dependent malignant behaviors in glioma stem cells. J Cell Physiol (2011) 226:1118-27. doi:10.1002/jcp.22433.
155. Parathath SR, Mainwaring LA, Fernandez-L A, Campbell DO, Kenney AM. Insulin receptor substrate 1 is an effector of sonic hedgehog mitogenic signaling in cerebellar neural precursors. Development (2008) 135:3291-300. doi:10.1242/dev.022871.
156. Kenney AM, Widlund HR, Rowitch DH. Hedgehog and PI-3 kinase signaling converge on Nmyc1 to promote cell cycle progression in cerebellar neuronal precursors. Development (2004) 131:217-28. doi:10.1242/dev.00891.
157. Browd SR, Kenney AM, Gottfried ON, Yoon JW, Walterhouse D, Pedone CA, et al. N-myc can substitute for insulin-like growth factor signaling in a mouse model of sonic hedgehog-induced medulloblastoma. Cancer Res (2006) 66:2666-72. doi:10.1158/0008-5472.CAN-05-2198.
158. Hartmann W, Koch A, Brune H, Waha A, Schüller U, Dani I, et al. Insulin-like growth factor II is involved in the proliferation control of medulloblastoma and its cerebellar precursor cells. Am J Pathol (2005) 166:1153-62. doi:10.1016/S0002-9440(10)62335-8.
159. Werner H, Shalita-Chesner M, Abramovitch S, Idelman G, Shaharabani-Gargir L, Glaser T. Regulation of the insulin-like growth factor-I receptor gene by oncogenes and antioncogenes: implications in human cancer. Mol Genet Metab (2000) 71:315-20. doi:10.1006/mgme.2000.3044.